Constitutive β-catenin signalling due to either inactivating mutations in APC or activating mutations within β-catenin itself also plays a critical role in the development of colon cancer; nearly 90% of all colon cancers harbour mutations that drive β-catenin signalling.11 Several small molecules that target the WNT pathway have been developed, and their inhibitory effects on tumour growth have been reported.11,12 Tankyrase inhibitors (TNKSi) induce stabilisation of AXIN, which abrogates WNT/β-catenin signalling and induces apoptosis. Here, AXIN1 is linked to malignant colon neoplasm.